World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT00004464
Date of registration: 18/10/1999
Prospective Registration: No
Primary sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Public title: Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Scientific title: High Dose Cyclophosphamide for the Treatment of Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Date of first enrolment: February 1996
Target sample size: 69
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT00004464
Study type:  Interventional
Study design:  Primary purpose: Treatment.  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Robert A. Brodsky
Address: 
Telephone:
Email:
Affiliation:  Johns Hopkins University
Key inclusion & exclusion criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

- Acquired severe aplastic anemia or paroxysmal nocturnal hemoglobinuria

- Not a candidate for allogeneic bone marrow transplantation

- Must meet one of the following criteria:

- Severe aplastic anemia

- Less than 25% bone marrow cellularity and depression in two of three blood
counts (reticulocytes less than 40,000/mm3

- platelet count less than 20,000/mm3 and granulocytes less than 500/mm3)

- Life-threatening paroxysmal nocturnal hemoglobinuria

- Absolute neutrophil count less than 500/mm3

- platelet transfusion dependent

- thrombotic disease

- No Fanconi anemia

- No abnormal cytogenetics

--Patient Characteristics--

- Renal: Creatinine no greater than 2.0 mg/dL

- Cardiovascular: Cardiac ejection fraction at least 45%

- Other: Not preterminal or moribund Not pregnant



Age minimum: N/A
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Paroxysmal Hemoglobinuria, Nocturnal
Aplastic Anemia
Intervention(s)
Drug: cyclophosphamide
Drug: filgrastim
Primary Outcome(s)
Secondary Outcome(s)
Secondary ID(s)
199/13895
96-01-17-02
JHOC-96011702
J9611
JHOC-9611
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history